lentiviral vector mediated hematopoietic stem progenitor cell gene therapy (SR-Tiget)

N/A

Report date: 2025/03/20 15:46:11

Base Information

Drug Namelentiviral vector mediated hematopoietic stem progenitor cell gene therapy (SR-Tiget)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapyCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vector

Mechanisms of ActionUpdating

TargetsUpdating

Therapy Area/IndicationsAdenosine deaminase deficiency

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryItaly

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesThe San Raffaele Telethon Institute For Gene Therapy

China Registration ClassN/A

Develop Information

Active CompaniesThe San Raffaele Telethon Institute For Gene Therapy

Inactive CompaniesN/A

Active IndicationsAdenosine deaminase deficiency

Inactive IndicationsN/A

Other Information

ATC CodeN/A